Significantly Higher Peripheral Insulin-Like Growth Factor-1 Levels in Patients With Major Depressive Disorder or Bipolar Disorder Than in Healthy Controls: A Meta-Analysis and Review Under Guideline of PRISMA
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
An increasing amount of research has focused on insulin-like growth factor-1 (IGF-1) because of multiple neurotrophic effects, including neurogenesis, remyelination, and synaptogenesis. In addition, IGF-1 can mediate an antidepressant effect in patients with major affective disorder, and its levels in the cerebrospinal fluid have been found to vary with antidepressant treatment. Furthermore, it has been proven to crossover the blood-brain barrier, with a reciprocal feedback loop being the central effect. However, recent studies have reported inconclusive findings about the role of IGF-1 in major affective disorder. The aim of the current study was to conduct a thorough meta-analysis of changes in peripheral IGF-1 levels in patients with major depressive disorder (MDD) or bipolar disorder (BD). We conducted a thorough literature search and compared peripheral IGF-1 levels in patients with MDD or BD and in healthy controls, and investigated clinical variables through meta-regression. Electronic research was conducted through platform of PubMed. We used inclusion criteria as clinical trials discussing comparisons of peripheral IGF-1 protein levels in patients with MDD or BD and those in healthy controls. We analyzed the cases from 9 studies with the random-effect model. The main finding was that peripheral IGF-1 levels in the patients were significantly higher than in the healthy controls (P < 0.001), with a significant inverse association with duration of illness (P = 0.03). In meta-analysis comparing peripheral IGF-1 levels in patients with BD or MDD before and after treatment, there was no significant change in peripheral IGF-1 levels after treatment (P = 0.092). The small numbers of studies and lack of correlation data with growth hormone in current studies are the main limitations of this meta-analysis. Our results indicated that peripheral IGF-1 levels may not be an indicator of disease severity, but may be a disease trait marker or an indicator of cognition. However, further investigations on the correlation between cognitive function and peripheral IGF-1 levels are needed to explore the role of IGF-1 in the pathophysiology of MDD and BD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slavich, G. M., & Irwin, M. R. (2014) · Psychological Bulletin · doi:10.1037/a0035302 · Cited by 2,206
Human growth hormone and human aging
CORPAS, E., HARMAN, S. M., & BLACKMAN, M. R. (1993) · Endocrine Reviews · doi:10.1210/edrv-14-1-20 · Cited by 911 · cited 1×
“From another point of view, the inverse association found in the current meta-analysis may be explained by somatopause, which means that the secretion of IGF-1 deceases with advancing age in healthy adults.(54,55) In the current meta-analysis, the peripheral IGF-1 levels did not significantly vary after adequate treat…”
ResultPeripheral Infusion of IGF-I Selectively Induces Neurogenesis in the Adult Rat Hippocampus
Åberg, M. A. I., Åberg, N. D., Hedbäcker, H., Oscarsson, J., & Eriksson, P. S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-08-02896.2000 · Cited by 852
Bone Mineral Density in Women with Depression
Michelson, D., Stratakis, C., Hill, L., Reynolds, J., Galliven, E., Chrousos, G., & Gold, P. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610173351602 · Cited by 471
O'Kusky, J. R., Ye, P., & D'Ercole, A. J. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-22-08435.2000 · Cited by 358
Munkholm, K., Vinberg, M., & Kessing, L. V. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.54 · Cited by 157
Krogh, J., Rostrup, E., Thomsen, C., Elfving, B., Videbech, P., & Nordentoft, M. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.04.041 · Cited by 123
Malberg, J. E., Platt, B., Rizzo, S. J. S., Ring, R. H., Lucki, I., Schechter, L. E., & Rosenzweig-Lipson, S. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301358 · Cited by 101 · cited 1×
“Studies Included in Each Meta-Analysis A total of 27 articles reached the screening stage, of which 4 were excluded because they focused on peripheral IGF-1 levels only in MDD patients without comparing the effects of treatment(31) or comparisons with healthy controls, 4 that focused on topics not related to BD or MDD…”
Possible contribution of IGF-1 to depressive disorder
Szczęsny, E., Ślusarczyk, J., Głombik, K., Budziszewska, B., Kubera, M., Lasoń, W., & Basta-Kaim, A. (2013) · Pharmacological Reports · doi:10.1016/s1734-1140(13)71523-8 · Cited by 68
IGF-I in major depression and antidepressant treatment response
Kopczak, A., Stalla, G. K., Uhr, M., Lucae, S., Hennings, J., Ising, M., Holsboer, F., & Kloiber, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.12.013 · Cited by 63
Cited by
The impact of frailty on intensive care unit outcomes: a systematic review and meta-analysis
Muscedere, J., Waters, B., Varambally, A., Bagshaw, S. M., Boyd, J. G., Maslove, D., Sibley, S., & Rockwood, K. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4867-0 · Cited by 827
“Our findings are consistent with the observation that frail patients are at increased risk of poor outcomes in other settings and after healthcare interventions [41, 42].”
ResultBiomarkers for depression: recent insights, current challenges and future prospects
Strawbridge, R., Young, A. H., & Cleare, A. J. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s114542 · Cited by 415
Evidence-based umbrella review of 162 peripheral biomarkers for major mental disorders
Carvalho, A. F., Solmi, M., Sanches, M., Machado, M. O., Stubbs, B., Ajnakina, O., Sherman, C., Sun, Y. R., Liu, C. S., Brunoni, A. R., et al. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0835-5 · Cited by 204
Peripheral Markers of Depression
Nobis, A., Zalewski, D., & Waszkiewicz, N. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123793 · Cited by 197
de Melo, L. G. P., Nunes, S. O. V., Anderson, G., Vargas, H. O., Barbosa, D. S., Galecki, P., Carvalho, A. F., & Maes, M. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.04.027 · Cited by 189
“…mood disorders may also be linked to insulin resistance, which is associated with alterations in insulin-like growth factor, immune and oxidative pathways and glucocorticoids (Belvederi Murri et al., 2016; Goldsmith et al., 2016; McIntyre et al., 2010; Stetler and Miller, 2011; Tu et al., 2016).”
Metadata
- Authors
- Tu, K.-Y., Wu, M.-K., Chen, Y.-W., Lin, P.-Y., Wang, H.-Y., Wu, C.-K., & Tseng, P.-T.
- Venue
- Medicine
- Published
- 2016-01
- Volume
- 95
- Issue
- 4
- Pages
- e2411
- ISSN
- 0025-7974 (ISSN-L)
- OpenAlex
- W2334471942
- Cited by
- 45
- References
- 11
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Significantly Higher Peripheral Insulin-Like Growth Factor-1 Levels in Patients With Major Depressive Disorder or Bipolar Disorder Than in Healthy Controls: A Meta-Analysis and Review Under Guideline of PRISMA. https://app.cochat.ai/papers/10.1097/md.0000000000002411
- The paper
- Tu, K.-Y., Wu, M.-K., Chen, Y.-W., Lin, P.-Y., Wang, H.-Y., Wu, C.-K., & Tseng, P.-T. (2016). Significantly Higher Peripheral Insulin-Like Growth Factor-1 Levels in Patients With Major Depressive Disorder or Bipolar Disorder Than in Healthy Controls: A Meta-Analysis and Review Under Guideline of PRISMA. Medicine. https://doi.org/10.1097/md.0000000000002411
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.